Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ: LEGN )

35.78 +1.05 (+3.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 982,204
Open 34.88
Bid (Size) 34.60 (6)
Ask (Size) 36.20 (3)
Prev. Close 34.73
Today's Range 34.84 - 36.24
52wk Range 32.08 - 70.13
Shares Outstanding 308,456,852
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Breaking Down Legend Biotech: 9 Analysts Share Their Views
Via Benzinga
Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire

Performance

YTD
+3.02%
+3.02%
1 Month
-14.11%
-14.11%
3 Month
-27.83%
-27.83%
6 Month
-24.53%
-24.53%
1 Year
-36.61%
-36.61%

More News

Read More
(LEGN) - Analyzing Legend Biotech's Short Interest
Via Benzinga
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
9 Analysts Have This To Say About Legend Biotech
Via Benzinga
Where Legend Biotech Stands With Analysts
Via Benzinga
Peering Into Legend Biotech's Recent Short Interest
Via Benzinga
CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
From Legend Biotech USA Inc.
Via GlobeNewswire
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
Via Benzinga
Looking Into Legend Biotech's Recent Short Interest
Via Benzinga
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
Via Benzinga
Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Appoints Alan Bash as President of CARVYKTI®
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
From Legend Biotech USA Inc.
Via GlobeNewswire
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Via Benzinga
CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
Via Investor's Business Daily
Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors
From Legend Biotech USA Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.